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ARE VAPE PENS THE NEW CIGARETTE? THE FDA’S IMPENDING QUEST TO
REGULATE THE E-CIGARETTE AND ITS EFFECT ON SOCIETY’S YOUTH
ADDISON J. MORGAN*
INTRODUCTION
Pursuant to the Food, Drug, and Cosmetic Act of 1938 (the “FDCA”), the Federal Drug
Administration (the “FDA”) has possessed the power to regulate food, drugs, and cosmetic
products for almost an entire century.1 The same cannot be said about tobacco products. Prior to
2009, tobacco products were largely exempt from federal health and safety laws.2 Nonetheless,
after the ratification of the Family Smoking Prevention and Tobacco Control Act of 2009, the FDA
was granted the authority necessary to regulate tobacco products.3 Despite being the primary
federal regulatory command with respect to tobacco, the FDA currently does not regulate the
cigarette’s distant counterpart: the e-cigarette.4
Since e-cigarettes were introduced into the United States in 2007, they have continuously
become popular among adolescents.5 According to the Centers for Disease and Control (the
“CDC”), high school student e-cigarette usage has increased by 78% since 2017 and that same
usage has increased by 48% among middle schoolers.6 Moreover, in 2017, the e-cigarette market
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See Federal Food, and Drug Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended at 21
U.S.C. §§ 301-397 (1994 & Supp. II 1997)).
2
See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 Stat. 1776 (2009).
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See FOOD & DRUG ADMIN., MODIFICATIONS TO COMPLIANCE POLICY FOR CERTAIN DEEMED TOBACCO PRODUCTS,
https://www.fda.gov/media/121384/download (last visited Apr. 19, 2019).
5
Kristy Marynak et al., Exposure to Electronic Cigarette Advertising Among Middle School and High School
Students – United States, 2014-2016, 67 MORBIDITY & MORTALITY WKLY. REP. 294, 298 (2018).
6
Karen A. Cullen et al., Notes from the Field: Use of Electronic Cigarettes and any Tobacco Product Among
Middle and High School Students – United States, 2011-2018, 67 MORBIDITY & MORTALITY WKLY. REP. 1276,
1276 (2018).

expanded by 40% to $1.16 billion.7 Majority of that economic growth is attributable to Juul, the
United States’ most prominent vaporizer manufacturer, whose vaping products have become quite
appealing due to wide array of flavored e-cigarette liquid offered by the corporation.8 In response
to the upward spike in adolescent e-cigarette usage, former FDA Commissioner Scott Gottlieb
issued a statement in 2018 discussing the proposed policy framework he sought to advance to
restrain youth appeal of e-cigarettes.9 Gottlieb’s proposed regulations would establish that all
flavored e-cigarette products (i.e., e-liquids and cartridge-based systems) must be sold in agerestricted, in-person locations to prevent underaged youth from accessing e-cigarette products
online.10
The ultimate objective of this article is to holistically assess the e-cigarette and its impact on
society’s youth and evaluate the probable implications generated by the FDA’s proposed ecigarette regulations. In Part I, I will explore tobacco’s vast history within the United States by
examining (1) the FDA’s legislative history, (2) the statute that purportedly authorized the agency
to assert jurisdiction over tobacco products, and (3) modern case law that limits the FDA’s
authoritative power to regulate tobacco products. In Part II, I will (1) examine the factors that have
contributed to the swift increase in adolescent e-cigarette usage as well as the safety data that
coincides with such usage, (2) analyze the FDA’s most recent e-cigarette regulations, and (3)
ascertain whether those restrictions are sufficient to curb youth appeal.
PART 1: HISTORICAL OVERVIEW OF THE FDA’S REGULATION OF TOBACCO

7

Julia Belluz, FDA: we might have to ban some e-cigarettes to stop teens from vaping, VOX,
https://www.vox.com/2018/9/12/17850598/fda-juul-vaping (last updated Sept. 21, 2018).
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Id.
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use, FOOD & DRUG ADMIN. (Sept. 11, 2018), https://www.fda.gov/news-events/press-announcements/statement-fdacommissioner-scott-gottlieb-md-new-steps-address-epidemic-youth-e-cigarette-use.
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Although cigarettes and tobacco products alike may be revered by some, the health
consequences engendered by tobacco usage have turned the lives of many Americans upside down.
The injurious nature of tobacco cannot be overstated. Cigarettes are responsible for more than
480,000 deaths per year in the United States and more than sixteen million Americans currently
live with a disease caused by smoking.11 As each day passes, more than 3,200 youth younger than
eighteen years of age smoke their first cigarette.12 Approximately 500,000 annual—albeit
preventable—deaths is a mystifying number. Surely the government was cognizant of the
multitude of health hazards associated with cigarette usage when Camel released an advertisement
in 1937 contending that its cigarettes assisted digestion by increasing the movement of alkaline
digestive fluids.13 Maybe it was aware, but then again, it is entirely plausible that the government
was genuinely ignorant of tobacco’s wounding nature. Even so, in order for the FDA to create
change and alter the cultural hegemony that, at the time, had completely inundated society with
unproven proclamations and deceitful advertisements concerning cigarette side effects, the FDA
needed unequivocal authoritative power.
In 1938, Congress passed the FDCA.14 The FDCA provided the FDA with the power to
regulate food, drugs, medical devices, and cosmetics.15 Specifically, the FDCA prohibits the “ . . .
introduction or delivery for introduction into interstate commerce of any food, drug, device or
cosmetic that is adulterated or misbranded.”16 The FDCA provided the FDA with an immense

Smoking & Tobacco Use, CTR.S’ FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/index.htm?s_cid=osh-stu-home-spotlight-001 (last visited
Nov. 17, 2019).
12
Id.
13
Cigarette Advertising Themes, STAN. UNIV. RES. INTO IMPACT TOBACCO ADVERT.,
http://tobacco.stanford.edu/tobacco_main/main.php (last visited Apr. 17, 2019).
14
How did the Federal Food, Drug, and Cosmetic Act come about?, FOOD & DRUG ADMIN.,
https://www.fda.gov/about-fda/fda-basics/how-did-federal-food-drug-and-cosmetic-act-come-about (last visited
Nov. 28, 2019).
15
21 U.S.C. § 301(a) (1994 & Supp. II 1997).
16
Id.
11

amount of power to enforce the FDCA’s statutory provisions.17 For example, the district courts of
the United States and the United States courts of the Territories have jurisdiction to issue
injunctions if provisions within the FDCA are violated.18 Moreover, any person who violates any
of the provisions enumerated in § 301 will be imprisoned for no more than a year or fined no more
than $1,000—or both.19 Lastly, the FDA may seize any article of food, drug, or cosmetic that is
adulterated or misbranded when such article is introduced, or discovered, in interstate commerce.20
These seized articles are proceeded against on libel of information and condemned in any district
court of the United States or United States court of a Territory within the jurisdiction where the
article is found.21 This type of plenary power was not at the FDA’s disposal under the FDCA’s
predecessor, the Food and Drug Act of 1906 (the “1906 Act”).22 The 1906 Act merely provided
each district attorney with power to commence legal proceedings to enforce the penalties of the
Act against parties who violated its provisions.23 Even so, the district attorney could only initiate
legal proceedings provided that satisfactory evidence of any violation of the Act was presented to
him or her by a health, food, or drug officer; or agent of any State, Territory, or the District of
Columbia.24 Even though the enactment of the FDCA mitigated the administrative shortcomings
of its predecessor and bestowed more authoritative power onto the FDA, the FDCA still possessed
its own deficiencies. Under the FDCA, the FDA did not have the authority to explicitly regulate
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tobacco and tobacco-related products.25 This deprivation of managerial control would become
accentuated in the coming years as tobacco usage—–and tobacco harm—drastically increased.
In light of the fact that many adolescents are introduced to cigarettes before their eighteenth
birthday, the FDA decided to intervene and do something that the agency had not done before.26
In August 1996, the FDA asserted jurisdiction—known as the FDA Rule of 1996—over cigarettes
and smokeless tobacco under the Federal Food, Drug, and Cosmetic Act.27 The FDA proclaimed
that it was permitted to assert jurisdiction over tobacco under the drug and device provisions of
the FDCA for the following reason:
“FDA has concluded that cigarettes and smokeless tobacco are combination
products consisting of nicotine, a drug that causes addiction and other significant
pharmacological effects on the human body, and device components that deliver
nicotine to the body . . . . This evidence includes the emergence of a scientific
consensus that cigarettes and smokeless tobacco cause addiction to nicotine and the
disclosure of thousands of pages of internal tobacco company documents detailing
that these products are intended by the manufacturers to affect the structure and
function of the human body.28
Pursuant to the FDCA, a product is a drug if it is an article (other than food) “intended to affect
the structure or any function of the body of man . . . .”29 Consequently, it was this provision that
catalyzed the FDA’s decision to devise a two-part conclusion explaining why it was permitted to
assert jurisdiction over tobacco.

25

Pursuant to the Federal Food, Drug, and Cosmetic Act, the FDA possessed the regulatory power to solely forbid
the introduction of adulterated tobacco products into interstate commerce; See also 21 U.S.C. § 301(a).
26
Youth and Tobacco, CTR.S’ FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/youth_data/tobacco_use/index.htm (last visited Nov. 17,
2019).
27
See Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed.
Reg. 44619, 45208 (Aug. 28, 1996).
28
Id. at 44629.
29
Federal Food, Drug, and Cosmetic Act § 201(g)(1)(C).

First, the FDA asserted that nicotine in cigarettes and smokeless tobacco does “affect the
structure or any function of the body.”30 The FDA’s contention was primarily based on nicotine’s
pharmacological effect on the structure and function of the user’s body.31 Nicotine creates an
addiction that induces repeated cigarette use merely to acquire more nicotine.32 Along with
dependency and addiction, nicotine also impairs the user’s nervous system and accelerates loss of
body weight.33 Because nicotine was analogous to drugs that the FDA had traditionally
regulated—“including stimulants, tranquilizers, [and] appetite suppressants . . .”—the FDA argued
that cigarettes and smokeless tobacco affected the “structure or any function of the body” within
the meaning of the FDCA.34
Second, the FDA asserted that the pharmacological effects generated by nicotine
metabolization were “intended” by the tobacco manufacturers.35 “Intended use” refers to the
objective intent of persons legally responsible for the labeling of drugs.36 Intent may be determined
by such persons’ expressions or may be shown by the circumstances surrounding distribution of
the article.37 Objective intent may be demonstrated by (1) labeling claims, (2) advertising matter,
or (3) oral or written statements.38 The FDA posited that a substantial amount of evidence indicated
that manufacturers intended for tobacco to affect the structure and function of the body: (1) the
evidence of the foreseeable pharmacological effects and uses of cigarettes and smokeless tobacco;
(2) the evidence of the actual consumer use of cigarettes and smokeless tobacco for
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Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg.
at 44629.
31
Id.
32
Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg.
at 44649.
33
Id. at 44632.
34
Id.
35
Id. at 44686.
36
See 21 C.F.R. § 201.128 (2019).
37
Id.
38
Id.

pharmacological purposes; and (3) the evidence of the statements, research, and actions of the
manufacturers themselves.39 Accordingly, because a robust, scientific consensus established that
cigarettes and smokeless tobacco caused nicotine addiction and many tobacco manufacturers
referred to nicotine as both “pharmacological agent[s]” and “extremely biologically active
compound[s],” the FDA contended that cigarettes were “intended” by tobacco manufacturers to
affect the structure and function of the body within the meaning of the FDCA.40
The FDA’s assertion of jurisdiction over cigarettes and smokeless tobacco products was not
premised on effectively banning nicotine.41 On the contrary, the FDA’s assertion of regulatory
control was predicated on the fact that “tobacco use [had] become . . . one of the most serious
public health problems facing the United States . . . .”42 Even though many states prohibited minors
from purchasing tobacco, minors still possessed unfettered access to tobacco products via vending
machines and over-the-counter sales.43 Based on these findings, the FDA promulgated a series of
regulations cemented on two fundamental objectives: (1) restricting access and (2) redefining
advertisements.44 The FDA sought to nullify the role marketing played in engraining the desire to
smoke in the adolescent mind by restricting cigarette advertisements to a black and white, textonly format.45 But if the advertisement appeared in a publication that was read almost exclusively
by adults, the restriction was inapplicable.46 Marketing regulations also prohibited outdoor
advertising within 1,000 feet of any public playground or school47; prohibited the distribution of
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Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg.
at 44687.
40
Id.
41
Id.
42
Id. at 45428.
43
Id. at 45244.
44
Id. at 45243.
45
See 21 C.F.R. § 897.32(a) (1996).
46
Id.
47
See 21 C.F.R. § 897.30(b) (1996).

any promotional items, such as T-shirts or hats bearing the tobacco manufacturer’s brand name48;
and prohibited tobacco manufacturers from sponsoring any athletic, musical, artistic, or cultural
event using its brand name.49 Access regulations prohibited the distribution of cigarettes via
vending machines; banned free samples; prohibited the sale of cigarettes to people under the age
of eighteen; and required retailers to check photo identification before making a sale.50 The FDA
presumably concluded that if the number of adolescents who begin tobacco use could be
substantially diminished, then the prevalence of tobacco-related illness could be correspondingly
reduced because scientific data suggested that anyone who did not begin smoking during their
adolescent years was unlikely to ever begin.51 The FDA hoped that its assertion of jurisdiction and
preliminary regulations would withstand a constitutional challenge. The livelihood of the FDA
Rule of 1996 was contingent upon the United States Supreme Court’s interpretation of the FDCA
in FDA v. Brown & Williamson.

Modern Case Law Limiting the FDA’s Regulatory Authority

In FDA v. Brown & Williamson, the Supreme Court of the United States was tasked with
determining whether the FDA was permitted to regulate tobacco products according to the express
language of the FDCA.52 The Court of Appeals for the Fourth Circuit held that Congress had not
granted the FDA jurisdiction to regulate tobacco products.53 According to the Fourth Circuit, it
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See 21 C.F.R. § 897.34(a) (1996).
See id. at § 897.34(c).
50
See 21 C.F.R. § 897.14 (1996).
51
Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg.
at 45238.
52
Food & Drug Admin. v. Brown & Williamson Tobacco Co., 120 S. Ct. 1291, 1297 (2000).
53
Id.
49

was impermissible for the FDA to assert jurisdiction over tobacco products because a number of
provisions within the FDCA require the FDA to ascertain whether any regulated product is “safe”
before it can be sold or allowed to remain on the market.54 Because the FDA had previously
declared that tobacco products were “dangerous” and “unsafe,” the Fourth Circuit concluded that
tobacco products could not be made safe and effective for their intended uses.55 Therefore, if
tobacco products fell within the scope of the FDA’s jurisdiction, the FDA would be forced to
remove tobacco products from the market immediately—a result that would be contrary to
congressional intent.56 Consequently, the Fourth Circuit reasoned that tobacco regulation was
forbidden under the FDCA’s present statutory framework.57 Surprisingly, before the FDA Rule of
1996, the FDA had repeatedly disclosed that tobacco products fell outside the agency’s regulatory
domain.58
The Supreme Court affirmed the Fourth Circuit’s ruling and held that Congress had not given
the FDA authority to assert jurisdiction over tobacco products.59 The Supreme Court based its
holding on two concrete principles: (1) the FDCA’s core objective was to ensure that any product
regulated by the FDA is “safe” and “effective” for its intended use 60 and (2) Congress enacted
tobacco-specific legislation against the backdrop of the FDA’s repeated statements that it lacked
authority under the FDCA to regulate tobacco absent claims of therapeutic benefit by the
manufacturer.61 Under the FDCA, the FDA shall prevent marketing of any drug or device where
the “potential for inflicting death or physical injury is not offset by the possibility of therapeutic

54

Id.
Id.
56
Id.; See also 7 U.S.C. § 1311(a) (2018) (repealed 2004).
57
Williamson & Brown Tobacco Co., 120 S. Ct. at 1299.
58
Id.
59
Id. at 1315.
60
Id. at 1301.
61
Id. at 1306.
55

benefit.”62 Additionally, for all devices regulated by the FDA, there must at least be a “reasonable
assurance of the safety and effectiveness of the device.”63 In its 1996 Rule, the FDA described the
adverse ramifications of tobacco usage in considerable detail, highlighting that “more than 400,000
people die each year from tobacco-related illnesses such as cancer, respiratory illnesses, and heart
disease, often suffering long and painful deaths . . . .”64 Because the FDA had continually
acknowledged that “tobacco products are unsafe,” “dangerous,” and “cause great pain and
suffering from illness,” it was statutorily impossible for the FDA to assert jurisdiction over tobacco
products.65 Once the FDA concludes that a drug or device cannot be used safely for any therapeutic
purpose, the FDA is barred from regulating such drug or device.66
The FDCA expressly emphasizes that any product regulated by the FDA must be safe for its
intended use.67 Although the FDA had determined that tobacco products are effective in
transmitting specific pharmacological effects to its users, those products deliver such effects in an
unsafe and dangerous manner.68 The Supreme Court decided that if tobacco products were within
the FDA’s reach pursuant to the FDCA, then the FDCA would require the FDA to eradicate
tobacco products entirely.69 But an indefinite ban on tobacco would contravene the tobaccospecific regulatory scheme set in place by Congress to address tobacco and health. 70 Thus, in the
words of the Court, “[i]f [tobacco products] cannot be used safely for any therapeutic purpose, and
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Id. at 1301.
21 U.S.C. § 393(b)(2)(C) (2018).
64
Brown & Williamson Tobacco Corp., 120 S. Ct. at 1302.
65
Id.
66
See id. at 1306.
67
Id.
68
Id.
69
Id.
70
Id.
63

yet [tobacco products] cannot be banned, [tobacco products] simply do not fit” within the confines
of the FDA’s regulatory power pursuant to the Federal Food, Drug and Cosmetic Act.71
After determining that the FDCA barred the FDA from exercising jurisdiction over tobacco
products, the Court confirmed its holding by evaluating the tobacco-specific legislation that
Congress had enacted.72 In response to the FDA’s proclamation that it lacked regulatory power,
Congress sought to implement its own regulatory scheme for tobacco products by enacting the
Alcohol and Drug Abuse Amendments in 1983, the Comprehensive Smoking Act in 1994, and the
Comprehensive Smokeless Tobacco Health Education Act of 1986.73 Many of these laws
precluded any administrative agency from playing a significant role in constructing tobacco
policy.74 For example, the Alcohol and Drug Abuse Amendments required the Secretary of Health
and Human Services to report directly to Congress every three years on the “addictive property of
tobacco” and to include recommendations for action that the Secretary may deem appropriate.75
The Supreme Court reasoned that Congress’s collective legislative action proscribed any
interpretation of the FDCA that would empower the FDA to regulate tobacco products.76 Congress
had developed a distinct regulatory scheme for the tobacco industry premised on the FDA’s
inability to regulate tobacco products.77 Thus, Congress “effectively ratified the FDA’s previous
position that it lack[ed] jurisdiction to regulate tobacco”—rendering the FDA’s 1996 Rule
invalid.78
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Id.
Id.
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Id. at 1311.
74
Id. at 1313.
75
Id. at 1311–12.
76
Id.
77
Id.
78
Id. at 1313.
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The Family Smoking Prevention and Tobacco Control Act and the FDA’s “Deeming” Authority

The Supreme Court’s decision in Brown v. Williamson invalidated the FDA’s 1996 Rule.79
Accordingly, even in light of congressional action, cigarette smoking continued to generate serious
illness resulting in approximately 440,000 annual deaths and $157 billion health-related economic
costs.80 Nearly a decade after the Brown decision, President Barack Obama ratified the Family
Smoking Prevention and Tobacco Control Act (“FSPTCA”), which gave the FDA sweeping
authority to regulate the manufacturing, marketing, and sale of tobacco products.81 The FSPTCA’s
predecessor, the FDCA, was premised on a public standard of “safety and efficacy.”82 Importantly,
the FSPTCA departed from the FDCA’s traditional standard as the more recent statute enables the
Secretary of Health and Human Services to regulate tobacco products in a manner that is
“appropriate for the protection of the public health.”83
The FSPTCA likely embodies a more hands-on, proactive standard because at the time the law
was enacted, Congress was thoroughly aware of tobacco’s effect on the health of not only society’s
adults—but its youth as well.84 Many adolescents are attracted to fruit assorted flavoring; therefore,
the FSPTCA prohibits cigarettes from containing an artificial or natural flavor (other than tobacco
or menthol), or an herb or spice, including “strawberry, grape, orange, clove, cinnamon, pineapple,
vanilla, coconut, licorice, cocoa, chocolate, cherry, or coffee” that acts as characterizing flavor of
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C. Husten et al., Cigarette Smoking Among Adults – United States, 2002, MORBIDITY & MORTALITY WKLY. REP.
(May 28, 2004), https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5320a2.htm.
81
Family Smoking Prevention and Tobacco Control Act § 910(a)-(c).
82
Federal Food, Drug, and Cosmetic Act § 306(g)(1)(A)(I).
83
Family Smoking Prevention and Tobacco Control Act § 907(a)(3)(A).
84
Id. at § 2(14).
80

the tobacco product or tobacco smoke.85 Furthermore, in an effort to combat public ignorance of
tobacco and health, the FSPTCA discloses that it is illegal for cigarette packages to be sold,
distributed, or imported for sale within the United States unless the package bears one of the labels
enumerated within the statute.86 For example, one label reads, “WARNING: Smoking can kill
you.”87 Although the FSPTCA authorized the FDA to promulgate certain marketing restrictions
and to increase the visibility of tobacco warning labels, the FDA’s true power under the FSPTCA
stems from its “deeming” authority.
The statutory provision that effectuates the FDA’s “deeming” authority states as follows: “This
chapter shall apply to all cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless
tobacco and to any other tobacco products that the Secretary by regulation deems to be subject to
this chapter.”88 Under the FSPTCA, a “tobacco product” is “any product made or derived from
tobacco that is intended for human consumption, including any component, part, or accessory of a
tobacco product (except for raw materials other than tobacco used in manufacturing a component,
part, or accessory of a tobacco product).”89 In 2016, acting under the “deeming” provision of the
FSPTCA, the FDA issued a final rule that extended the Agency’s “tobacco product” authority to
all other categories of products that meet the FSPTCA’s definition of “tobacco.”90 According to
the FDA, the terms “component” and “part” embedded in the FSPTCA’s “tobacco product”
definition refer to “any software or assembly of materials intended or reasonably expected to (1)
alter or affect the tobacco product’s performance, composition, constituents or characteristics; or
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Id. at § 907(a)(1)(A).
Id. at § 201(a)(1).
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Id. at § 901(b) (emphasis added).
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Id. at § 101(rr)(1).
90
See Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, 81 Fed. Reg. 28974,
28975 (2016).
86

(2) to be used with or for the human consumption of a tobacco product.”91 These terms acted as
regulatory hooks for the FDA, thereby expanding the FDA’s authoritative reach to components
and parts used with electronic nicotine delivery systems (“ENDS”).92 Examples of ENDS
components and parts that fall within the scope of the FDA’s regulatory command are e-cigarettes,
E-liquids, atomizers, batteries and cartomizers.93 The FDA’s “deeming” authority begs the
question: if the FDA has definite, unambiguous authority to ultimately subject any tobacco product
to the provisions enumerated within the FSPTCA, why is adolescent e-cigarette usage at an alltime high?

PART II: A SPIKE IN ADOLESCENT E-CIGARETTE USAGE: A CAUSE FOR
CONCERN

Since 2011, e-cigarette usage has increased at an exponential rate; in 2014, e-cigarettes became
the most commonly used tobacco among middle school and high school students.94 Specifically,
in 2014, 16% of 10th graders reported use of e-cigarettes in the past 30 days and 43% of those
students reported that he or she had never smoked a combustible cigarette.95 This statistic is
unsettling because it undoubtedly exemplifies the rationale that encourages a vast majority of
society’s youth to partake in e-cigarette usage: many adolescents—even those who have yet to
smoke a Marlboro or Kool—adamantly believe that by smoking e-cigarettes, they are covertly
evading the damaging side-effects linked to combustible cigarettes. Youth are impressionable; the
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Tushar Singh et al., Vital Signs: Exposure to Electronic Cigarette Advertising Among Middle School and High
School Students – United States, 2014, 64 MORBIDITY & MORTALITY WKLY. REP. 1403, 1403–08 (2016).
95
Adam M. Leventhal et al., Association of Electronic Cigarette Use with Initiation of Combustible Tobacco
Product Smoking in Early Adolescence, 314 [J]AMA 700, 700–07 (2015).
92

way in which an e-cigarette delivers nicotine to its user naturally induces curiosity in second-hand
viewers. In a 2015 survey, e-cigarette consumers were asked to disclose the most important reason
for utilizing the device.96 Tellingly, the response garnering the most submissions was “to
experiment—to see what [e-cigarettes are] like.”97 Despite the fact that the decision to
“experiment” with a device possessing such convoluted intricacies may indeed be a naive and
uninformed one, should society’s youth themselves solely bear the blame for this uptick in ecigarette usage or should the blame be allocated to the FDA for failing to have the foresight
necessary to prevent this phenomenon from occurring? The short answer: blame both.
A. What is an e-cigarette and how is it mechanized?
Electronic cigarettes are primarily battery-powered devices capable of delivering nicotine to
its user in an aerosol form.98 When a user activates an e-cigarette, a metal coil is heated which in
turn vaporizes a solution (i.e., e-liquid) mainly consisting of propylene glycol, vegetable glycerin,
distilled water, and flavorings that frequently contain nicotine.99 This mechanism of action is
colloquially referred to as “vaping” and nicotine, which is dissolved inside the e-liquid, is released
in the aerosolized vapor produced by the heated coil inside the e-cigarette.100
A combustible cigarette is mechanized in a drastically different fashion.101 Combustible
cigarettes are activated by a process commonly known as “combustion.”102 Combustion requires
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Id.

the user of the cigarette to ignite the end of the cigarette with fire.103 Once the cigarette is ignited,
the combination of tobacco, fire, and oxygen induces a self-sustaining combustion process that
continuously engulfs the tobacco.104 Principally, it is this combustion process that has prompted
the substantial increase in adolescent e-cigarette usage over the years.105 From the layman’s
perspective, combustible cigarettes create smoke and that smoke contains volatile components that
induce fatal and debilitating health disorders.106 Because e-cigarette aerosols neither involve
combustion nor tobacco smoke, adolescents have concluded that e-cigarettes are safer than
combustible cigarettes.107 Notably, boundless empirical data exist substantiating the adolescent
presumptive deduction: combustible cigarettes accounted for over 48% of all cancer-related deaths
between 2005-2009 and cause more than 7 million deaths per year.108 Still, do the previous
statistics definitively suggest that inhalation of aerosols emitted from e-cigarette devices are safer
than the smoke emitted by a combustible cigarette?

B. Are e-cigarettes safer than combustible cigarettes?

Many e-cigarettes and all combustible cigarettes deliver nicotine to their respective users.
Nicotine, a highly addictive chemical, has not been deemed carcinogenic in humans.109 Scientific
studies suggest that combustible cigarette byproducts generate most of cigarette smoke’s harmful
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health effects—primarily cancer.110 Therefore, the belief that the e-cigarette is a safer alternative
must be assessed. It must be determined whether such belief is compelling or wholly conjectural.

i.

Combustible Cigarettes and Cancer

Outside of nicotine, combustible cigarettes—via the smoke emitted—generate approximately
7,000 toxic compounds and more than 70 identified carcinogens.111 At the moment the cigarette is
ignited, the compounds present in the cigarette smoke undergo complex chemical reactions; the
duration and extent of these chemical reactions is dependent upon the number of puffs taken by a
user and puff duration.112 Both factors induce extreme variability in the number of toxins produced
over the life of a single cigarette.113 The process that activates carcinogens in cigarette smoke is
referred to as tobacco carcinogenesis.114 Despite the fact that cancer’s biological pathway remains
an unfortunate mystery, tobacco carcinogenesis can be explained by examining rudimentary
scientific principles. For cigarette smokers who develop cancer, cancer inception begins with
nicotine as the substance’s addictive properties provoke an overindulgence in combustible
cigarette usage.115 In turn, this progressively heightened usage of combustible cigarettes inundates
the user’s body with an unfathomable number of carcinogens.116 As the carcinogens are
metabolically activated, DNA adducts, which consists of carcinogen metabolites covalently
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bonded to DNA, form.117 At this stage, DNA bound to carcinogens either (1) normalizes itself
through enzymatic repair mechanisms (i.e., covalent bond between carcinogen and DNA is
destroyed) or (2) the DNA adduct persists and carcinogenesis commences.118 This persistence may
prompt genetic miscoding, which may ultimately result in a permanent mutation of DNA.119
Chronic tobacco smokers unconsciously trigger this process an innumerable amount of times over
the course of their lives and the potential for permanent, genetic mutations acutely increases as a
result.120

ii.

Combustible Cigarettes and Cardiovascular Disease

It is well-documented that combustible cigarette use is responsible for a variety of disorders
including cardiovascular disease, which is the single largest cause of death in the United States,
killing more than 800,000 people a year.121 Tobacco smoke is an independent risk factor of
cardiovascular atherosclerosis.122 Atherosclerosis, the process by which the arteries narrow and
become less flexible,123 has been conclusively linked to tobacco smoking.124 But the underlying
causal nexus between tobacco smoke and atherosclerosis has not yet been discovered. 125 On the
surface, inhalation of tobacco smoke—even secondhand smoke—has the potential to directly
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damage artery walls and severely impair endothelial function, thereby inhibiting vasodilation of
normal coronary arteries and reducing coronary flow reserve.126 Moreover, combustible cigarettes
have been associated with evidence of chronic inflammation127 of the arteries and this
inflammatory response is a symptom of atherosclerosis.128 A number of studies have demonstrated
that smoking causes a 20-25% increase in the peripheral blood leukocyte count and an increased
level of inflammatory markers.129 Cigarette smoking leads to elevations of various
proinflammatory cytokines and an increase in leukocyte-endothelial cell interaction which leads
to leukocyte recruitment—an event triggered early on in the development of atherosclerosis.
Tellingly, a study has documented that these inflammatory markers return to their baseline levels
five years after smoking cessation; this not only indicates that cigarette-induced cardiovascular
disease may be reversible, it also reveals that tobacco smoke is the primary trigger of inflammation
in the blood and at the vessel wall.130

iii.

E-Cigarette Safety and the Renormalization of Smoking

According to an independent evidence review published by Public Health England
(“PHE”) in 2015, best estimates specify that “e-cigarettes are 95% less harmful to [one’s] health
than [combustible] cigarettes, and when supported by a smoking cessation service, [e-cigarettes]
help most smokers . . . quit tobacco altogether.”131 Admittedly, the preceding data seems earnestly
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sensible; e-cigarettes deliver nicotine to its user in a manner that appears to circumvent the unstable
combustion process that is responsible for subjecting conventional cigarette users to a plethora of
ailments.132 Although PHE’s data seems to be commonsensical, the organization failed to proffer
any legitimate scientific data substantiating its position and instead, the organization relied solely
upon a single meeting of 12 people convened to develop a multicriteria decision analysis (MDCA)
model to synthesize their opinions on the harms associated with different nicotine products.133
Even though PHE’s evidence review was premised on inadequate methodological practices,
PHE explicitly contended that “there is no evidence to date that [e-cigarettes] are [renormalizing]
smoking . . . .”134 This assertion is utterly false on its face as it has been documented that ecigarettes became the most commonly used form of tobacco by middle school and high school
students in 2014.135 Though PHE argued that the e-cigarette cannot be characterized as a gateway
to combustible cigarettes, one American study arrived at a different conclusion suggesting that
“[high school students] who used electronic cigarettes at baseline compared with non-user [high
school students] were more likely to report initiation of combustible tobacco use over the next
year.”136 Although safety data suggest that e-cigarettes contain lower levels of toxic substances
than combustible cigarettes,137 the e-cigarette’s impact on society’s health is generally unknown.138
Accordingly, speculative claims—like the proclamations made by PHE—run the risk of
renormalizing smoking.139 “Renormalization” of smoking has the potential to render the potential
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benefits that stem from e-cigarette usage irrelevant if, by and through such usage, society’s
nicotine dependence increases by way of a restored approval of smoking in general.140
E-cigarettes are extremely novel devices and that novelty evinces that it is irrefutably
premature to support (let alone consciously disseminate) information purporting that e-cigarettes
are categorically safer than combustible cigarettes. Recently, the FDA disclosed that e-cigarettes
may be associated with seizures as the agency has received 35 reports of e-cigarette induced
seizures since 2010.141 Moreover, vaping-related illnesses and deaths have proliferated out of thin
air.142 Since the e-cigarette’s inception in 2007, the CDC and the FDA have reported six-vaping
related deaths.143 Every single vaping-related death has occurred in 2019.144 Some of the deceased
were young and completely healthy minutes before they were hospitalized for acute lung disease;
others were old and frail.145 Health officials believe that vitamin E acetate—a chemical used
primarily in cannabis-containing vaping products—is to blame.146 But neither the CDC nor the
FDA have identified an explicit causal link between vaping and the preceding deaths.147 Yet, ecigarettes and its progeny remain on the market, flavorful and unregulated. At first glance, it seems
pointless for these agencies to disclose such a small number of vaping-related seizures and deaths
to the general public. But it is not the diminutive magnitude of the quantity of seizures and deaths
that is alarming. On the contrary, it is the fact that such disclosure illuminates that the safety data
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associated with e-cigarette usage is unresolved and inconclusive. As a result, an e-cigarette should
be utilized in a fashion that mirrors the device’s present uncertainty.

C. Who is truly at fault: the adolescents for making primarily uneducated decisions or the
FDA for failing to regulate e-cigarettes?

Even though it may be true that most adolescents who partake in recreational e-cigarette use
do so without holistically assessing the consequences of that decision, it is also true that the FDA
is obligated—by virtue that its existence is inextricably tied to protecting the public health—to
inhibit the birth of such a decision. Presently, the FDA’s “deeming rule” prohibits e-cigarette
retailers from (1) selling e-cigarettes to customers age 17 and younger;148 (2) distributing free
samples; and (3) selling e-cigarettes in vending machines.149 On the other hand, e-cigarette
manufacturers are solely prohibited from distributing free samples.150 Failure to comply with these
regulations may render an e-cigarette adulterated, misbranded, or both, and it is unlawful for any
entity to sell or distribute an adulterated and/or misbranded product in interstate commerce.151
Clearly, the FDA has instituted express regulations to curb, not only youth appeal, but youth
access to e-cigarettes. So, what’s the problem? Admittedly, the FDA has made major strides in the
realm of e-cigarette regulation. Still, those strides do not overshadow or negate the fact that
Congress effectuates laws for those laws to be fully complied with. All products and devices that
the FDA has identified to be “tobacco products” pursuant to its “deeming” authority became
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subject to the premarket authorization requirements of the FSPTCA as of August 8, 2016.152
Premarket authorization requires that the product manufacturer receive FDA approval of its
premarket approval application before the manufacturer markets the device.153 Before the FDA
grants a manufacturer premarket approval for a product, the FDA assesses the validity of the
scientific evidence associated with the manufacturer’s application to confirm that the proposed
product is safe and effective for its intended use.154 In accordance with the FSPTCA, any
manufacturer that seeks to introduce a tobacco product intended for human use into interstate
commerce must first attain premarket authorization from the FDA.155 However, if the tobacco
product that the manufacturer proposes to introduce into interstate commerce was commercially
marketed in the United States prior to February 15, 2007 or the product is “substantially
equivalent” to a product that has been previously granted premarket authorization by the FDA,
then the FSPTCA’s premarket authorization requirements are inapplicable.156 Simply put,
manufacturers of “new” tobacco products (i.e., products that were commercially marketed in
interstate commerce after February 15, 2007) that have not received authorization to be introduced
or delivered into interstate commerce via an FDA substantial equivalence order, must file a
premarket authorization application with the FDA containing “full reports of all information . . .
concerning investigations which have been made to show the health risks of such tobacco product
. . . .”157
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It has been documented that peer-reviewed toxicology information of the world’s leading ecigarette brands is extremely limited.158 Consequently, many, if not all, the premarket approval
applications that would be submitted by manufacturers of “new” tobacco products would utterly
fail to satisfy the requirement of informing the FDA of the “health risks” associated with such
“new” tobacco products.159 Unsurprisingly, the scarcity of information concerning the health
hazards triggered by e-cigarette usage should—conceivably—restrict a “new” tobacco product’s
access to interstate commerce on account of the fact that its manufacturer cannot provide the FDA
with the requisite information for premarket authorization. However, instead of transforming the
preceding reasonable hypothesis into a reality by strictly enforcing § 910 of the FDCA, former
FDA Commissioner Scott Gottlieb made an executive decision to allow “new” e-cigarettes to
remain unconstrained on the market until August 8, 2021.160 After that date passes, the FDA has
asserted that it “intends to prioritize enforcement for lack of a [premarket authorization] against
flavored ENDS products.”161 Furthermore, the FDA has disclosed that its “decision to prioritize
enforcement of [§ 910 of the FD&C Act] against a manufacturer and/or retailer will continue to
be determined on a case-by-case basis.”162
The FDA’s reasoning for effectively destroying the efficacy of the FDCA is that e-cigarettes
have the potential to help adult smokers make the transition “completely off of combustible
products.”163 This is undoubtedly a possibility; it is also entirely possible that the intrinsic
properties of vitamin C may one day empower the nutrient to kill cancer.164 Regardless, this mere
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possibility must be juxtaposed against the definitive fact that middle schoolers do not possess the
intellectual wherewithal to properly evaluate the consequences—many of which are unknown165—
of partaking in recreational e-cigarette usage.166 Importantly, in 2013, it was documented that 61.1
% of middle school and 80% of high school e-cigarette-using students reported that they smoked
combustible cigarettes in conjunction with e-cigarettes.169 Conversely, 20.3% and 7.2% of students
within those respective groups who documented that they had never smoked an e-cigarette
similarly reported that they had never smoked a combustible cigarette either.170 The correlation
between adolescent e-cigarette usage and adolescent combustible cigarette usage is uncomfortably
astounding. The preceding data illustrates that youth who smoke e-cigarettes are inclined to smoke
combustible cigarettes. On the other hand, if an adolescent is prohibited from “ripping” a Juul
during his juvenile years, then it is highly unlikely—nearly theoretically impossible—that he will
develop an e-cigarette-induced propensity to smoke Camels or Marlboros. Therefore, the FDA’s
actions to date not only clearly defy the FSPTCA, but those actions also fail to sufficiently protect
the health of the future citizenry of the United States.
CONCLUSION
In order to truly combat the epidemic rise in adolescent e-cigarette usage, the solution is quite
simple. The FDA must earnestly enforce the FDCA and institute immediate regulations that firmly
encroach upon the ability of society’s youth to obtain e-cigarettes. If the FDA continues to defer
to e-cigarette manufacturers and retailers, misinformation will linger, deaths will inevitably ensue,
and the health of youth nationwide will continue to progressively decline. Tellingly, the
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unrestrained adolescent usage of e-cigarettes has prompted many states to enact statutes that place
strict limitations on public e-cigarette consumption.171 The FDA must follow suit because if ecigarettes continue to be conspicuously utilized, then smoking behavior will be expeditiously
destigmatized. Destigmatization of smoking will place future generations of youth at an intolerable
disadvantage—a disadvantage that can ultimately be deemed null and void if the FDA’s
forthcoming acts resolutely embody the administrative agency’s underlying purpose: protection of
public health.
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